Unlocking the potential of
genomic medicine

2017 News Releases

Date Title
Toggle Summary04/02/2015
PHILADELPHIA , April 2, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, April 17, 2015 at 8:30 a.m. ET to discuss first quarter 2015 financial results. In order to participate in the conference call, please dial (844) 466-4113
Toggle Summary03/02/2015
PHILADELPHIA , March 2, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan
Toggle Summary02/13/2015
Click here for PDF Click here for Word Proof of concept established for TARGT TM platform Enrollment initiated in mid-dose arm of MDGN-201 study; low-dose arm fully enrolled Preclinical peptide programs advancing Prioritizing CHOP collaboration programs PHILADELPHIA , Feb.
Toggle Summary01/30/2015
Click here for PDF Click here for Word PHILADELPHIA , Jan. 30, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results.
Toggle Summary01/08/2015
Click here for PDF Click here for Word PHILADELPHIA , Jan. 8, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue